Not a good buy right now: trend is bearish (SMA_200 > SMA_20 > SMA_5) and momentum is weakening (MACD histogram negative and expanding).
No Intellectia buy signals today (AI Stock Picker and SwingMax both show no signal), so there’s no strong tactical edge for an immediate entry.
Fundamentals show modest revenue growth but profitability deterioration (net income and EPS down sharply), which doesn’t support an impatient “buy now” decision.
If you already hold, this is more of a hold/monitor near support (2.085–2.067) rather than add; if you don’t own it, avoid initiating until price reclaims the pivot (~2.116) and momentum stabilizes.
Technical Analysis
Price: 2.10, sitting below the pivot (2.116) and close to support (S1 2.085; S2 2.067), suggesting fragility rather than strength.
Trend: Bearish structure with SMA_200 > SMA_20 > SMA_5 (downtrend across long/medium/short term).
Gross margin improved to 22.12% (+13.03% YoY), which is one of the few constructive trends in the latest quarter.
Price is near defined support (2.085–2.067), where short-term technical bounces can occur if selling pressure fades.
No significant negative insider/hedge fund trend flagged recently (both reported as neutral).
Neutral/Negative Catalysts
indicates the path of least resistance is still down.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: $7.171M, +2.46% YoY (modest growth).
Profitability: Net income -$17K, -91.79% YoY (meaningful deterioration).
EPS: 0, -100% YoY (loss of earnings power vs prior year).
Gross margin: 22.12%, +13.03% YoY (improvement, but not translating into stronger bottom-line results yet).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Provided analyst update shows: [2025-12-04] JPMorgan cut price target (EUR 75 → EUR 71) while maintaining an Overweight rating — however, the note references Amadeus IT Group, which does not align with American Shared Hospital Services (AMS), so it’s likely not applicable to this stock.
Wall Street pro/con view based strictly on usable data here: Pros = some margin improvement and modest revenue growth; Cons = weak/declining profitability and bearish technicals, with no clear, credible analyst catalyst in the provided feed.
Wall Street analysts forecast AMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMS is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast AMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMS is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Buy
Hold
Sell
0
Current: 2.200
Low
0
Averages
0
High
0
0
Current: 2.200
Low
0
Averages
0
High
0
JPMorgan
Overweight
to
NULL
downgrade
AI Analysis
2025-12-04
Reason
JPMorgan
Price Target
AI Analysis
2025-12-04
downgrade
Overweight
to
NULL
Reason
JPMorgan lowered the firm's price target on Amadeus IT Group to EUR 71 from EUR 75 and keeps an Overweight rating on the shares.
